98 related articles for article (PubMed ID: 8394886)
1. Three-dimensional dosimetry for radioimmunotherapy treatment planning.
Sgouros G; Chiu S; Pentlow KS; Brewster LJ; Kalaigian H; Baldwin B; Daghighian F; Graham MC; Larson SM; Mohan R
J Nucl Med; 1993 Sep; 34(9):1595-601. PubMed ID: 8394886
[TBL] [Abstract][Full Text] [Related]
2. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
Kolbert KS; Sgouros G; Scott AM; Bronstein JE; Malane RA; Zhang J; Kalaigian H; McNamara S; Schwartz L; Larson SM
J Nucl Med; 1997 Feb; 38(2):301-8. PubMed ID: 9025759
[TBL] [Abstract][Full Text] [Related]
3. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy.
Giap HB; Macey DJ; Podoloff DA
J Nucl Med; 1995 Oct; 36(10):1885-94. PubMed ID: 7562060
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry.
Yoriyaz H; Stabin MG; dos Santos A
J Nucl Med; 2001 Apr; 42(4):662-9. PubMed ID: 11337557
[TBL] [Abstract][Full Text] [Related]
5. [Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma].
Dhermain F; Ducreux D; Bidault F; Bruna A; Parker F; Roujeau T; Beaudre A; Armand JP; Haie-Meder C
Bull Cancer; 2005 Apr; 92(4):333-42. PubMed ID: 15888390
[TBL] [Abstract][Full Text] [Related]
6. Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).
Wessels BW; Syh JH; Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S39-45. PubMed ID: 16979438
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
[TBL] [Abstract][Full Text] [Related]
8. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.
Pauwels S; Barone R; Walrand S; Borson-Chazot F; Valkema R; Kvols LK; Krenning EP; Jamar F
J Nucl Med; 2005 Jan; 46 Suppl 1():92S-8S. PubMed ID: 15653657
[TBL] [Abstract][Full Text] [Related]
9. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
10. Delineation of target volume for radiotherapy of high-grade gliomas by 99m Tc-MIBI SPECT and MRI fusion.
Krengli M; Loi G; Sacchetti G; Manfredda I; Gambaro G; Brambilla M; Carriero A; Inglese E
Strahlenther Onkol; 2007 Dec; 183(12):689-94. PubMed ID: 18040614
[TBL] [Abstract][Full Text] [Related]
11. A radionuclide therapy treatment planning and dose estimation system.
Liu A; Williams LE; Lopatin G; Yamauchi DM; Wong JY; Raubitschek AA
J Nucl Med; 1999 Jul; 40(7):1151-3. PubMed ID: 10405136
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging.
Flux GD; Webb S; Ott RJ; Chittenden SJ; Thomas R
J Nucl Med; 1997 Jul; 38(7):1059-66. PubMed ID: 9225791
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the influence of setup uncertainties on treatment planning for focal liver tumors.
Balter JM; Brock KK; Lam KL; Tatro D; Dawson LA; McShan DL; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):610-4. PubMed ID: 16095848
[TBL] [Abstract][Full Text] [Related]
15. [Image registration for radiation therapy: Practical aspects and quality control].
Bonniaud G; Isambert A; Dhermain F; Beaudré A; Ferreira I; Ricard M; Lefkopoulos D
Cancer Radiother; 2006 Sep; 10(5):222-30. PubMed ID: 16890471
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy of liver metastases. Comparison of target volumes and dose-volume histograms employing CT- or MRI-based treatment planning.
Pech M; Mohnike K; Wieners G; Bialek E; Dudeck O; Seidensticker M; Peters N; Wust P; Gademann G; Ricke J
Strahlenther Onkol; 2008 May; 184(5):256-61. PubMed ID: 18427756
[TBL] [Abstract][Full Text] [Related]
17. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
18. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides.
Sgouros G; Barest G; Thekkumthala J; Chui C; Mohan R; Bigler RE; Zanzonico PB
J Nucl Med; 1990 Nov; 31(11):1884-91. PubMed ID: 2231006
[TBL] [Abstract][Full Text] [Related]
19. Dose mapping: validation in 4D dosimetry with measurements and application in radiotherapy follow-up evaluation.
Zhang GG; Huang TC; Forster KM; Lin KP; Stevens C; Harris E; Guerrero T
Comput Methods Programs Biomed; 2008 Apr; 90(1):25-37. PubMed ID: 18178288
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain?
Hermanto U; Frija EK; Lii MJ; Chang EL; Mahajan A; Woo SY
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1135-44. PubMed ID: 17208388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
